Juno Pharmaceuticals Canada
Paul Varady is a highly experienced professional in the field of Regulatory Affairs and Quality Management, currently serving as Vice President of Quality and Regulatory Affairs at Juno Pharmaceuticals Canada since April 2022. With a career spanning over two decades, Varady has held key positions including Chief Scientific Officer at Seaford Pharmaceuticals, President of RegCon Solutions, and Director of Regulatory Affairs at SteriMax. Varady has a strong track record of developing and executing comprehensive regulatory strategies, overseeing product approvals, and maintaining compliance across multiple regions, including Canada, the EU, and the US. In addition to practical experience, Varady has also contributed to academic institutions as an instructor, teaching Regulatory Writing and Communications at Seneca College and other courses. Varady holds a Bachelor of Science degree in Biology from York University.
This person is not in any teams
This person is not in any offices
Juno Pharmaceuticals Canada
Juno Pharmaceuticals Canada sources, develops, and delivers life saving specialized pharmaceutical products for Canadian patients. Our colleagues work with trusted partners to co-develop novel drug delivery mechanisms that satisfy untapped market demand, first to market generic products, biosimilar offerings, and patent challenge strategies. Juno’s portfolio consists of both branded and generic drug assets in multiple presentation forms including injectable drugs (vials, amps, & pre filled syringes), complex biosimilars, ophthalmic products, oral does tablets and capsules, prescription dermatology topicals, and other unique dosage systems. Our team have deep roots into the Canadian hospital space, retail pharmacy market, specialty channels, and a robust B2B platform. In addition, Juno Canada has recently embarked with product sourcing in the animal health space and remain focused on opening new delivery channels and customer groups to facilitate supply for Canadian patients. Juno is proud to supply 5 molecules deemed medically necessary by the World Health Organization on their critically essential medications list, and we are actively pursuing export opportunities to countries in need of our critical medications. To learn more about Juno Pharmaceuticals Canada please contact us at communications@junopharm.com For sales enquiries contact us at sales@junopharm.com